The COVID-19 pandemic brings unprecedented disaster for public well being and economics on this planet. Detecting particular antibodies to SARS-CoV-2 is a strong complement for the prognosis of COVID-19 and is necessary for epidemiological research and vaccine validations.
Herein, a fast and quantitative detection technique of anti-SARS-CoV-2 IgG antibody was constructed based mostly on the optofluidic point-of-care testing fluorescence biosensor. With out difficult steps wanted, the moveable system is appropriate for on-site delicate willpower of anti-SARS-CoV-2 IgG antibody in serum.
Underneath the optimum circumstances, the entire detection process is about 25 min with a detection restrict of 12.5 ng/mL that may effectively meet the diagnostic necessities. The tactic was not clearly affected by IgM and serum matrix and demonstrated to have good stability and reliability in actual pattern evaluation.
In comparison with ELISA take a look at outcomes, the proposed technique reveals a number of benefits together with wider measurement vary and simpler operation. The tactic gives a common platform for fast and quantitative evaluation of different associated biomarkers, which is of significance for the prevention and management of COVID-19 pandemic.
Change to infliximab subcutaneous throughout SARS-CoV-2 pandemic: preliminary outcomes
A brand new subcutaneous formulation of the infliximab biosimilar CT-P13 has lately been developed for the remedy of inflammatory bowel illness (IBD), offering response charges much like intravenous remedy. In an effort to restrict affected person attendance at intravenous infusion facilities and to keep up organic remedy in the course of the COVID-19 pandemic, using this new formulation was requested.
The target of this observational, retrospective, and descriptive examine was to evaluate CT-P13 efficacy and security after switching from intravenous to subcutaneous formulation in sufferers with IBD receiving upkeep remedy. This text reveals preliminary outcomes after six months of follow-up.
Neutralizing Monoclonal Antibodies That Goal the Spike Receptor Binding Area Confer Fc Receptor-Unbiased Safety towards SARS-CoV-2 An infection in Syrian Hamsters
The extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the principle goal for neutralizing antibodies. These antibodies might be elicited by immunization or passively transferred as therapeutics within the type of convalescent-phase sera or monoclonal antibodies (MAbs). Potently neutralizing antibodies are anticipated to confer safety; nonetheless, it’s unclear whether or not weakly neutralizing antibodies contribute to safety.
Additionally, their mechanism of motion in vivo is incompletely understood. Right here, we exhibit that 2B04, an antibody with an ultrapotent neutralizing exercise (50% inhibitory focus [IC50] of 0.04 μg/ml), protects hamsters towards SARS-CoV-2 in a prophylactic and therapeutic an infection mannequin.
Safety is related to diminished weight reduction and viral hundreds in nasal turbinates and lungs after problem. MAb 2B04 additionally blocked aerosol transmission of the virus to naive contacts. We subsequent examined three further MAbs (2C02, 2C03, and 2E06), recognizing distinct epitopes inside the receptor binding area of spike protein that possess both minimal (2C02 and 2E06, IC50 > 20 μg/ml) or weak (2C03, IC50 of 5 μg/ml) virus neutralization capability in vitro. Solely 2C03 protected Syrian hamsters from weight reduction and diminished lung viral load after SARS-CoV-2 an infection.
Lastly, we demonstrated that Fc-Fc receptor interactions weren’t required for cover when 2B04 and 2C03 had been administered prophylactically. These findings inform the mechanism of safety and help the rational growth of antibody-mediated safety towards SARS-CoV-2 infections. IMPORTANCE The continuing coronavirus illness 2019 (COVID-19) pandemic, brought on by SARS-CoV-2, has resulted within the lack of thousands and thousands of lives.
Secure and efficient vaccines are thought-about the final word treatment for the worldwide social and financial disruption brought on by the pandemic. Nevertheless, an intensive understanding of the immune correlates of safety towards this virus is missing. Right here, we characterised 4 completely different monoclonal antibodies and evaluated their skill to forestall or deal with SARS-CoV-2 an infection in Syrian hamsters. These antibodies different of their skill to neutralize the virus in vitro.
Prophylactic administration of potent and weakly neutralizing antibodies protected towards SARS-CoV-2 an infection, and this impact was Fc receptor unbiased. The potent neutralizing antibody additionally had therapeutic efficacy and eradicated onward aerosol transmission.
In distinction, minimally neutralizing antibodies supplied no safety towards an infection with SARS-CoV-2 in Syrian hamsters. Mixed, these research spotlight the importance of weakly neutralizing antibodies within the safety towards SARS-CoV-2 an infection and related illness.
Manufacturing of full-length SARS-CoV-2 nucleocapsid protein from Escherichia coli optimized by native hydrophobic interplay chromatography hyphenated to multi-angle mild scattering detection
The nucleocapsid protein (NP) of extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is vital for a number of steps of the viral life cycle, and is abundantly expressed throughout an infection, making it a really perfect diagnostic goal protein.
This protein has a robust tendency for dimerization and interplay with nucleic acids. For the primary time, excessive titers of NP had been expressed in E. coli with a CASPON tag, utilizing a growth-decoupled protein expression system.
Purification was completed by nuclease remedy of the cell homogenate and a sequence of downstream processing (DSP) steps. An analytical technique consisting of native hydrophobic interplay chromatography hyphenated to multi-angle mild scattering detection (HIC-MALS) was established for in-process management, specifically, to observe product fragmentation and multimerization all through the purification course of.
730 mg purified NP per liter of fermentation may very well be produced by the optimized course of, equivalent to a yield of 77% after cell lysis. The HIC-MALS technique was used to exhibit that the NP product might be produced with a purity of 95%. The molecular mass of the principle NP fraction is according to dimerized protein as was verified by a complementary native size-exclusion separation (SEC)-MALS evaluation.
Peptide mapping mass spectrometry and host cell particular enzyme-linked immunosorbent assay confirmed the excessive product purity, and the presence of a minor endogenous chaperone defined the residual impurities.
SARS (IN3) Spike Peptide |
|
3225P |
ProSci |
0.05 mg |
EUR 197.7 |
|
Description: (IN) SARS (IN3) Spike peptide |
SARS (IN3) Spike Peptide |
|
MBS152121-005mg |
MyBiosource |
0.05mg |
EUR 175 |
SARS (IN3) Spike Peptide |
|
MBS152121-5x005mg |
MyBiosource |
5x0.05mg |
EUR 770 |
SARS (IN1) Spike Peptide |
|
MBS153092-005mg |
MyBiosource |
0.05mg |
EUR 175 |
SARS (IN1) Spike Peptide |
|
MBS153092-5x005mg |
MyBiosource |
5x0.05mg |
EUR 770 |
SARS (IN2) Spike Peptide |
|
MBS153171-005mg |
MyBiosource |
0.05mg |
EUR 175 |
SARS (IN2) Spike Peptide |
|
MBS153171-5x005mg |
MyBiosource |
5x0.05mg |
EUR 770 |
SARS-CoV-2 Spike Peptide |
|
9083P |
ProSci |
0.05 mg |
EUR 235.5 |
|
Description: (NT) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike Peptide |
|
9087P |
ProSci |
0.05 mg |
EUR 235.5 |
|
Description: (CT) SARS-CoV-2 Spike RBD peptide |
SARS-CoV-2 Spike Peptide |
|
9091P |
ProSci |
0.05 mg |
EUR 235.5 |
|
Description: (IN) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike Peptide |
|
9095P |
ProSci |
0.05 mg |
EUR 235.5 |
|
Description: (IN) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike Peptide |
|
abx620083-100g |
Abbexa |
100 µg |
EUR 250 |
SARS-CoV-2 Spike Peptide |
|
abx620083-1mg |
Abbexa |
1 mg |
EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|
abx620083-200g |
Abbexa |
200 µg |
EUR 350 |
SARS-CoV-2 Spike Peptide |
|
abx620084-100g |
Abbexa |
100 µg |
EUR 250 |
SARS-CoV-2 Spike Peptide |
|
abx620084-1mg |
Abbexa |
1 mg |
EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|
abx620084-200g |
Abbexa |
200 µg |
EUR 350 |
SARS-CoV-2 Spike Peptide |
|
abx620085-100g |
Abbexa |
100 µg |
EUR 250 |
SARS-CoV-2 Spike Peptide |
|
abx620085-1mg |
Abbexa |
1 mg |
EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|
abx620085-200g |
Abbexa |
200 µg |
EUR 350 |
SARS-CoV-2 Spike Peptide |
|
abx620086-100g |
Abbexa |
100 µg |
EUR 250 |
SARS-CoV-2 Spike Peptide |
|
abx620086-1mg |
Abbexa |
1 mg |
EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|
abx620086-200g |
Abbexa |
200 µg |
EUR 350 |
SARS-CoV-2 Spike Peptide |
|
abx620087-100g |
Abbexa |
100 µg |
EUR 250 |
SARS-CoV-2 Spike Peptide |
|
abx620087-1mg |
Abbexa |
1 mg |
EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|
abx620087-200g |
Abbexa |
200 µg |
EUR 350 |
SARS-CoV-2 Spike Peptide |
|
abx620088-100g |
Abbexa |
100 µg |
EUR 250 |
SARS-CoV-2 Spike Peptide |
|
abx620088-1mg |
Abbexa |
1 mg |
EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|
abx620088-200g |
Abbexa |
200 µg |
EUR 350 |
SARS-CoV-2 Spike Peptide |
|
abx620089-100g |
Abbexa |
100 µg |
EUR 250 |
SARS-CoV-2 Spike Peptide |
|
abx620089-1mg |
Abbexa |
1 mg |
EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|
abx620089-200g |
Abbexa |
200 µg |
EUR 350 |
SARS-CoV-2 Spike Peptide |
|
MBS154644-005mg |
MyBiosource |
0.05mg |
EUR 205 |
SARS-CoV-2 Spike Peptide |
|
MBS154644-5x005mg |
MyBiosource |
5x0.05mg |
EUR 900 |
SARS-CoV-2 Spike Peptide |
|
MBS154645-005mg |
MyBiosource |
0.05mg |
EUR 205 |
SARS-CoV-2 Spike Peptide |
|
MBS154645-5x005mg |
MyBiosource |
5x0.05mg |
EUR 900 |
SARS-CoV-2 Spike Peptide |
|
MBS154646-005mg |
MyBiosource |
0.05mg |
EUR 205 |
SARS-CoV-2 Spike Peptide |
|
MBS154646-5x005mg |
MyBiosource |
5x0.05mg |
EUR 900 |
SARS-CoV-2 Spike Peptide |
|
MBS154655-005mg |
MyBiosource |
0.05mg |
EUR 205 |
SARS-CoV-2 Spike Peptide |
|
MBS154655-5x005mg |
MyBiosource |
5x0.05mg |
EUR 900 |
SARS-CoV-2 Spike S2 Peptide |
|
9119P |
ProSci |
0.05 mg |
EUR 235.5 |
|
Description: (IN) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike S2 Peptide |
|
9123P |
ProSci |
0.05 mg |
EUR 235.5 |
|
Description: (CT) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike S2 Peptide |
|
MBS154693-005mg |
MyBiosource |
0.05mg |
EUR 205 |
SARS-CoV-2 Spike S2 Peptide |
|
MBS154693-5x005mg |
MyBiosource |
5x0.05mg |
EUR 900 |
SARS-CoV-2 Spike S2 Peptide |
|
MBS154694-005mg |
MyBiosource |
0.05mg |
EUR 205 |
SARS-CoV-2 Spike S2 Peptide |
|
MBS154694-5x005mg |
MyBiosource |
5x0.05mg |
EUR 900 |
SARS-CoV-2 Spike RBD 319-335 peptide |
|
SB086 |
Smartox Biotechnology |
1 |
EUR 111.03 |
|
Description: SARS-CoV-2 Spike RBD 319-335 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 319-335 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 319-335 (Biotin-LC) peptide |
SARS-CoV-2 Spike RBD 336-347 peptide |
|
SB087 |
Smartox Biotechnology |
1 |
EUR 99.34 |
|
Description: SARS-CoV-2 Spike RBD 336-347 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 336-347 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 336-347 (Biotin-LC) peptide |
SARS-CoV-2 Spike RBD 348-357 peptide |
|
SB088 |
Smartox Biotechnology |
1 |
EUR 93.5 |
|
Description: SARS-CoV-2 Spike RBD 348-357 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 348-357 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 348-357 (Biotin-LC) peptide |
SARS-CoV-2 Spike RBD 352-365 peptide |
|
SB089 |
Smartox Biotechnology |
1 |
EUR 105.19 |
|
Description: SARS-CoV-2 Spike RBD 352-365 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 352-365 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 352-365 (Biotin-LC) peptide |
SARS-CoV-2 Spike RBD 371-394 peptide |
|
SB090 |
Smartox Biotechnology |
1 |
EUR 128.56 |
|
Description: SARS-CoV-2 Spike RBD 371-394 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 371-394 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 371-394 (Biotin-LC) peptide |
SARS-CoV-2 Spike RBD 395-430 peptide |
|
SB091 |
Smartox Biotechnology |
1 |
EUR 151.94 |
|
Description: SARS-CoV-2 Spike RBD 395-430 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 395-430 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 395-430 (Biotin-LC) peptide |
SARS-CoV-2 Spike RBM 438-458 peptide |
|
SB092 |
Smartox Biotechnology |
1 |
EUR 116.88 |
|
Description: SARS-CoV-2 Spike RBM 438-458 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Motif (RBM). SARS-CoV-2 Spike RBM 438-458 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBM: The receptor-binding domain in SARS-CoV-2 Spike protein contains a receptor-binding motif RBM. SARS-CoV-2 Spike RBM is the main functional motif in RBD and allows contacts between the S protein and the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBM 438-458 (Biotin-LC) peptide |
SARS-CoV-2 Spike RBM 450-473 peptide |
|
SB093 |
Smartox Biotechnology |
1 |
EUR 128.56 |
|
Description: SARS-CoV-2 Spike RBM 450-473 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Motif (RBM). SARS-CoV-2 Spike RBM 450-473 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBM: The receptor-binding domain in SARS-CoV-2 Spike protein contains a receptor-binding motif RBM. SARS-CoV-2 Spike RBM is the main functional motif in RBD and allows contacts between the S protein and the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBM 450-473 (Biotin-LC) peptide |
SARS-CoV-2 Spike RBM 480-496 peptide |
|
SB094 |
Smartox Biotechnology |
1 |
EUR 111.03 |
|
Description: SARS-CoV-2 Spike RBM 480-496 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Motif (RBM). SARS-CoV-2 Spike RBM 480-496 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBM: The receptor-binding domain in SARS-CoV-2 Spike protein contains a receptor-binding motif RBM. SARS-CoV-2 Spike RBM is the main functional motif in RBD and allows contacts between the S protein and the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBM 480-496 (Biotin-LC) peptide |
SARS-CoV-2 Spike RBM 500-509 peptide |
|
SB095 |
Smartox Biotechnology |
1 |
EUR 93.5 |
|
Description: SARS-CoV-2 Spike RBM 500-509 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Motif (RBM). SARS-CoV-2 Spike RBM 500-509 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBM: The receptor-binding domain in SARS-CoV-2 Spike protein contains a receptor-binding motif RBM. SARS-CoV-2 Spike RBM is the main functional motif in RBD and allows contacts between the S protein and the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBM 500-509 (Biotin-LC) peptide |
SARS-CoV-2 Spike RBD 513-520 peptide |
|
SB096 |
Smartox Biotechnology |
1 |
EUR 93.5 |
|
Description: SARS-CoV-2 Spike RBD 513-520 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 513-520 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 513-520 (Biotin-LC) peptide |
SARS-CoV-2 Spike RBD 523-541 peptide |
|
SB097 |
Smartox Biotechnology |
1 |
EUR 151.94 |
|
Description: SARS-CoV-2 Spike RBD 523-541 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 523-541 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 523-541 (Biotin-LC) peptide |
SARS-CoV-2 Spike P26S Peptide (Gamma Variant) |
|
9573P |
ProSci |
0.05 mg |
EUR 235.5 |
|
Description: SARS-CoV-2 Spike P26S Peptide (Gamma Variant) |
SARS-CoV-2 Spike P26S Peptide (Gamma Variant) |
|
MBS154835-005mg |
MyBiosource |
0.05mg |
EUR 205 |
SARS-CoV-2 Spike P26S Peptide (Gamma Variant) |
|
MBS154835-5x005mg |
MyBiosource |
5x0.05mg |
EUR 900 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 1 |
|
MBS156039-005mg |
MyBiosource |
0.05mg |
EUR 275 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 1 |
|
MBS156039-01mg |
MyBiosource |
0.1mg |
EUR 350 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 1 |
|
MBS156039-1mg |
MyBiosource |
1mg |
EUR 1175 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 1 |
|
MBS156039-5x1mg |
MyBiosource |
5x1mg |
EUR 4960 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 2 |
|
MBS156040-005mg |
MyBiosource |
0.05mg |
EUR 275 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 2 |
|
MBS156040-01mg |
MyBiosource |
0.1mg |
EUR 350 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 2 |
|
MBS156040-1mg |
MyBiosource |
1mg |
EUR 1175 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 2 |
|
MBS156040-5x1mg |
MyBiosource |
5x1mg |
EUR 4960 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 3 |
|
MBS156041-005mg |
MyBiosource |
0.05mg |
EUR 275 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 3 |
|
MBS156041-01mg |
MyBiosource |
0.1mg |
EUR 350 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 3 |
|
MBS156041-1mg |
MyBiosource |
1mg |
EUR 1175 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 3 |
|
MBS156041-5x1mg |
MyBiosource |
5x1mg |
EUR 4960 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 4 |
|
MBS156042-005mg |
MyBiosource |
0.05mg |
EUR 275 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 4 |
|
MBS156042-01mg |
MyBiosource |
0.1mg |
EUR 350 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 4 |
|
MBS156042-1mg |
MyBiosource |
1mg |
EUR 1175 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 4 |
|
MBS156042-5x1mg |
MyBiosource |
5x1mg |
EUR 4960 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 5 |
|
MBS156043-005mg |
MyBiosource |
0.05mg |
EUR 275 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 5 |
|
MBS156043-01mg |
MyBiosource |
0.1mg |
EUR 350 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 5 |
|
MBS156043-1mg |
MyBiosource |
1mg |
EUR 1175 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 5 |
|
MBS156043-5x1mg |
MyBiosource |
5x1mg |
EUR 4960 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 6 |
|
MBS156044-005mg |
MyBiosource |
0.05mg |
EUR 275 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 6 |
|
MBS156044-01mg |
MyBiosource |
0.1mg |
EUR 350 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 6 |
|
MBS156044-1mg |
MyBiosource |
1mg |
EUR 1175 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 6 |
|
MBS156044-5x1mg |
MyBiosource |
5x1mg |
EUR 4960 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 7 |
|
MBS156045-005mg |
MyBiosource |
0.05mg |
EUR 275 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 7 |
|
MBS156045-01mg |
MyBiosource |
0.1mg |
EUR 350 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 7 |
|
MBS156045-1mg |
MyBiosource |
1mg |
EUR 1175 |
SARS-CoV-2 (2019-nCoV) Spike protein peptide 7 |
|
MBS156045-5x1mg |
MyBiosource |
5x1mg |
EUR 4960 |
SARS-CoV-2/COVID-19 Spike Protein (Peptide 6) |
|
E40COV392 |
EnoGene |
N/A |
EUR 346.5 |
|
Description: N/A |
SARS-CoV-2/COVID-19 Spike Protein (Peptide 5) |
|
E40COV394 |
EnoGene |
N/A |
EUR 346.5 |
|
Description: N/A |
SARS-CoV-2/COVID-19 Spike Protein (Peptide 7) |
|
E40COV395 |
EnoGene |
N/A |
EUR 346.5 |
|
Description: N/A |
SARS-CoV-2/COVID-19 Spike Protein (Peptide 4) |
|
E40COV397 |
EnoGene |
N/A |
EUR 346.5 |
|
Description: N/A |
SARS-CoV-2/COVID-19 Spike Protein (Peptide 3) |
|
E40COV400 |
EnoGene |
N/A |
EUR 346.5 |
|
Description: N/A |
SARS-CoV-2/COVID-19 Spike Protein (Peptide 1) |
|
E40COV402 |
EnoGene |
N/A |
EUR 346.5 |
|
Description: N/A |
SARS-CoV-2/COVID-19 Spike Protein (Peptide 2) |
|
E40COV403 |
EnoGene |
N/A |
EUR 346.5 |
|
Description: N/A |
SARS-CoV-2 Spike Protein (437-509) / Receptor Binding Motif EIA Kit |
|
EK-071-75 |
PHOENIX PEPTIDE |
96 wells |
EUR 596.16 |
SARS virus Spike Antibody (N-term D204) Blocking Peptide |
|
MBS9225884-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
SARS, Spike Protein (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus) (Control Peptide) |
|
MBS655128-005mg |
MyBiosource |
0.05mg |
EUR 395 |
SARS, Spike Protein (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus) (Control Peptide) |
|
MBS655128-5x005mg |
MyBiosource |
5x0.05mg |
EUR 1630 |
SARS, Spike Protein (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus) (Control Peptide) |
|
MBS655134-005mg |
MyBiosource |
0.05mg |
EUR 395 |
SARS, Spike Protein (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus) (Control Peptide) |
|
MBS655134-5x005mg |
MyBiosource |
5x0.05mg |
EUR 1630 |
SARS, Spike Protein (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus) (Control Peptide) |
|
MBS655164-005mg |
MyBiosource |
0.05mg |
EUR 395 |
SARS, Spike Protein (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus) (Control Peptide) |
|
MBS655164-5x005mg |
MyBiosource |
5x0.05mg |
EUR 1630 |
SARS, Spike Protein (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus) (Control Peptide) |
|
MBS655210-005mg |
MyBiosource |
0.05mg |
EUR 395 |
SARS, Spike Protein (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus) (Control Peptide) |
|
MBS655210-5x005mg |
MyBiosource |
5x0.05mg |
EUR 1630 |
SARS, Spike Protein (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus) (Control Peptide) |
|
MBS655236-005mg |
MyBiosource |
0.05mg |
EUR 395 |
SARS, Spike Protein (Severe Acute Respiratory Syndrome, SARS-CoV, SARS Associated Coronavirus) (Control Peptide) |
|
MBS655236-5x005mg |
MyBiosource |
5x0.05mg |
EUR 1630 |
SARS-CoV-2 (COVID-19) Spike P681R Peptide (Delta Variant) |
|
9673P |
ProSci |
0.05 mg |
EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) Spike P681R Peptide (Delta Variant) |
SARS-CoV-2 (COVID-19) Spike P681R Peptide (Delta Variant) |
|
MBS154845-005mg |
MyBiosource |
0.05mg |
EUR 200 |
SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike P681H Peptide |
|
9359P |
ProSci |
0.05 mg |
EUR 235.5 |
|
Description: SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike P681H Peptide |
SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike P681H Peptide |
|
MBS154834-005mg |
MyBiosource |
0.05mg |
EUR 205 |
SARS-CoV-2 (COVID-19) Alpha Variant (B.1.1.7, UK) Spike P681H Peptide |
|
MBS154834-5x005mg |
MyBiosource |
5x0.05mg |
EUR 900 |
SARS Spike |
|
ant-157 |
ProSpec Tany |
5µg |
EUR 175 |
|
Description: Polyclonal Rabbit Anti SARS Spike Protein |
SARS Spike |
|
ant-758 |
ProSpec Tany |
5µg |
EUR 175 |
|
Description: Mouse Anti SARS Spike |
Biotin-SARS-CoV-2 Spike RBD 319-335 peptide |
|
SB098 |
Smartox Biotechnology |
1 |
EUR 133.24 |
|
Description: Biotin-SARS-CoV-2 Spike RBD 319-335 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 319-335 peptide. SARS-CoV-2 Spike RBD 319-335 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 319-335 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. |
Biotin-SARS-CoV-2 Spike RBD 336-347 peptide |
|
SB099 |
Smartox Biotechnology |
1 |
EUR 119.21 |
|
Description: Biotin-SARS-CoV-2 Spike RBD 336-347 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 336-347 peptide. SARS-CoV-2 Spike RBD 336-347 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 336-347 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. |
Biotin-SARS-CoV-2 Spike RBD 348-357 peptide |
|
SB100 |
Smartox Biotechnology |
1 |
EUR 112.2 |
|
Description: Biotin-SARS-CoV-2 Spike RBD 348-357 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 348-357 peptide. SARS-CoV-2 Spike RBD 348-357 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 348-357 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. |
Biotin-SARS-CoV-2 Spike RBD 352-365 peptide |
|
SB101 |
Smartox Biotechnology |
1 |
EUR 126.23 |
|
Description: Biotin-SARS-CoV-2 Spike RBD 352-365 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 352-365 peptide. SARS-CoV-2 Spike RBD 352-365 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 352-365 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. |
Biotin-SARS-CoV-2 Spike RBD 371-394 peptide |
|
SB102 |
Smartox Biotechnology |
1 |
EUR 154.28 |
|
Description: Biotin-SARS-CoV-2 Spike RBD 371-394 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 371-394 peptide. SARS-CoV-2 Spike RBD 371-394 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 371-394 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. |
Biotin-SARS-CoV-2 Spike RBD 395-430 peptide |
|
SB103 |
Smartox Biotechnology |
1 |
EUR 182.33 |
|
Description: Biotin-SARS-CoV-2 Spike RBD 395-430 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 395-430 peptide. SARS-CoV-2 Spike RBD 395-430 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 395-430 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. |
Biotin-SARS-CoV-2 Spike RBM 438-458 peptide |
|
SB104 |
Smartox Biotechnology |
1 |
EUR 140.25 |
|
Description: Biotin-SARS-CoV-2 Spike RBM 438-458 peptide is the biotinylated version of SARS-CoV-2 Spike RBM 438-458 peptide. SARS-CoV-2 Spike RBM 438-458 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Motif (RBM). Biotin-SARS-CoV-2 Spike RBM 438-458 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBM: The receptor-binding domain in SARS-CoV-2 Spike protein contains a receptor-binding motif RBM. SARS-CoV-2 Spike RBM is the main functional motif in RBD and allows contacts between the S protein and the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. |
Biotin-SARS-CoV-2 Spike RBM 450-473 peptide |
|
SB105 |
Smartox Biotechnology |
1 |
EUR 154.28 |
|
Description: Biotin-SARS-CoV-2 Spike RBM 450-473 peptide is the biotinylated version of SARS-CoV-2 Spike RBM 450-473 peptide. SARS-CoV-2 Spike RBM 450-473 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Motif (RBM). Biotin-SARS-CoV-2 Spike RBM 450-473 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBM: The receptor-binding domain in SARS-CoV-2 Spike protein contains a receptor-binding motif RBM. SARS-CoV-2 Spike RBM is the main functional motif in RBD and allows contacts between the S protein and the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. |
Biotin-SARS-CoV-2 Spike RBM 480-496 peptide |
|
SB106 |
Smartox Biotechnology |
1 |
EUR 133.24 |
|
Description: Biotin-SARS-CoV-2 Spike RBM 480-496 (Biotin-LC) peptide is the biotinylated version of SARS-CoV-2 Spike RBM 480-496 peptide. SARS-CoV-2 Spike RBM 480-496 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Motif (RBM). Biotin-SARS-CoV-2 Spike RBM 480-496 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBM: The receptor-binding domain in SARS-CoV-2 Spike protein contains a receptor-binding motif RBM. SARS-CoV-2 Spike RBM is the main functional motif in RBD and allows contacts between the S protein and the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. |
Biotin-SARS-CoV-2 Spike RBM 500-509 peptide |
|
SB107 |
Smartox Biotechnology |
1 |
EUR 112.2 |
|
Description: Biotin-SARS-CoV-2 Spike RBM 500-509 peptide is the biotinylated version of SARS-CoV-2 Spike RBM 500-509 peptide. SARS-CoV-2 Spike RBM 500-509 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Motif (RBM). Biotin-SARS-CoV-2 Spike RBM 500-509 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBM: The receptor-binding domain in SARS-CoV-2 Spike protein contains a receptor-binding motif RBM. SARS-CoV-2 Spike RBM is the main functional motif in RBD and allows contacts between the S protein and the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. |
Biotin-SARS-CoV-2 Spike RBD 513-520 peptide |
|
SB108 |
Smartox Biotechnology |
1 |
EUR 112.2 |
|
Description: Biotin-SARS-CoV-2 Spike RBD 513-520 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 513-520 peptide. SARS-CoV-2 Spike RBD 513-520 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 513-520 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. |
Biotin-SARS-CoV-2 Spike RBD 523-541 peptide |
|
SB109 |
Smartox Biotechnology |
1 |
EUR 182.33 |
|
Description: Biotin-SARS-CoV-2 Spike RBD 523-541 peptide is the biotinylated version of SARS-CoV-2 Spike RBD 523-541 peptide. SARS-CoV-2 Spike RBD 523-541 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). Biotin-SARS-CoV-2 Spike RBD 523-541 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. |
SARS Spike (1-666) |
|
sars-025 |
ProSpec Tany |
50µg |
EUR 900 |
|
Description: Recombinant SARS Associated Coronavirus Spike (1-666 a.a.) |
SARS Spike (14-667) |
|
sars-031 |
ProSpec Tany |
2µg |
EUR 60 |
|
Description: Recombinant SARS Associated Coronavirus Spike (14-667 a.a.) |
SARS Spike (306-527) |
|
sars-032 |
ProSpec Tany |
50µg |
EUR 900 |
|
Description: Recombinant SARS Associated Coronavirus Spike Receptor Binding Domain (306-527 a.a.) |
SARS Spike (306-515) |
|
sars-046 |
ProSpec Tany |
2µg |
EUR 60 |
|
Description: Recombinant SARS Associated Coronavirus Spike Receptor Binding Domain (306-515 a.a.) |
SARS Spike (14-1195) |
|
sars-048 |
ProSpec Tany |
2µg |
EUR 60 |
|
Description: Recombinant SARS Associated Coronavirus Spike (14-1195 a.a.) |
SARS Spike Mosaic |
|
sars-010 |
ProSpec Tany |
50µg |
EUR 165 |
|
Description: Recombinant SARS Associated Spike Mosaic |
Spike S peptide pool |
|
SB124 |
Smartox Biotechnology |
15 nmol |
EUR 409.06 |
|
Description: Spike S peptide is a peptide pool made of 15-mer peptides with 11–amino acid (aa) overlap, covering the complete sequence of the Spike S protein. |
SARS Spike Antibody |
|
24216 |
SAB |
100ul |
EUR 479 |
SARS Spike Antibody |
|
24216-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
|
24217 |
SAB |
100ul |
EUR 479 |
SARS Spike Antibody |
|
24217-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
|
24218 |
SAB |
100ul |
EUR 479 |
SARS Spike Antibody |
|
24218-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
|
24219 |
SAB |
100ul |
EUR 479 |
SARS Spike Antibody |
|
24219-100ul |
SAB |
100ul |
EUR 468 |
The optimized HIC-MALS technique allows monitoring of the product purity, and concurrently entry its molecular mass, offering orthogonal data complementary to established SEC-MALS strategies. Enhanced resolving energy might be achieved over SEC, attributed to the prolonged variables to tune selectivity in HIC mode.